Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.96 USD | -5.26% | +7.03% | +12.82% |
Financials (USD)
Sales 2024 * | 24.88M | Sales 2025 * | 32.7M | Capitalization | 248M |
---|---|---|---|---|---|
Net income 2024 * | -10M | Net income 2025 * | -26M | EV / Sales 2024 * | 9.98 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 7.6 x |
P/E ratio 2024 * |
-21.7
x | P/E ratio 2025 * |
-9.63
x | Employees | 10 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.9% |
Latest transcript on Aldeyra Therapeutics, Inc.
1 day | -5.26% | ||
1 week | +7.03% | ||
Current month | +2.59% | ||
1 month | -4.81% | ||
3 months | +0.76% | ||
6 months | +26.92% | ||
Current year | +12.82% |
Managers | Title | Age | Since |
---|---|---|---|
Todd Brady
CEO | Chief Executive Officer | 52 | 05-08-31 |
Bruce Greenberg
DFI | Director of Finance/CFO | 56 | 19-11-30 |
Caitlin Pazzano
PRN | Corporate Officer/Principal | - | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Phillips
BRD | Director/Board Member | 58 | 09-04-30 |
Martin Joyce
BRD | Director/Board Member | 70 | 13-09-30 |
Ben Bronstein
BRD | Director/Board Member | 74 | 10-05-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +4.23% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-06 | 3.96 | -5.26% | 174,491 |
24-06-05 | 4.18 | +2.20% | 187,544 |
24-06-04 | 4.09 | +6.51% | 426,946 |
24-06-03 | 3.84 | -0.52% | 458,171 |
24-05-31 | 3.86 | +3.49% | 274,081 |
Delayed Quote Nasdaq, June 06, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.82% | 248M | |
+19.33% | 125B | |
+13.95% | 109B | |
-3.53% | 24.74B | |
+2.71% | 22.67B | |
-9.95% | 18.14B | |
-41.48% | 16.67B | |
-12.62% | 16.64B | |
+0.99% | 13.45B | |
+21.79% | 11.32B |
- Stock Market
- Equities
- ALDX Stock